2024
Interferon regulatory factor 4 plays a pivotal role in the development of aGVHD-associated colitis.
Frueh, J.T., Campe, J., Sunaga-Franze, D.Y., Verheyden, N.A., Ghimire, S., Meedt, E., Haslinger, D., Harenkamp, S., Staudenraus, D., Sauer, S., Kreft, A., Schubert, R., Lohoff, M., Krueger, A., Bonig, H., Chiocchetti, A.G., Zeiser, R., Holler, E. and Ullrich, E.
OncoImmunology 13
(1): 2296712.
2024
2022
Conventional amphotericin B elicits markers of immunogenic cell death on leukemic blasts, mediates immunostimulatory effects on phagocytic cells, and synergizes with PD-L1 blockade.
Kofla, G., Radecke, C., Frentsch, M., Walther, W., Stintzing, S., Riess, H., Bullinger, L. and Na, I.K.
OncoImmunology 11
(1): 2068109.
25 April 2022
2020
Better prognosis of gastric cancer patients with high levels of tumor infiltrating lymphocytes is counteracted by PD-1 expression.
Pötzsch, M., Berg, E., Hummel, M., Stein, U., von Winterfeld, M., Jöhrens, K., Rau, B., Daum, S. and Treese, C.
OncoImmunology 9
(1): 1824632.
30 September 2020
2019
Human Mesenchymal glioblastomas are characterized by an increased immune cell presence compared to Proneural and Classical tumors.
Kaffes, I., Szulzewsky, F., Chen, Z., Herting, C.J., Gabanic, B., Velázquez Vega, J.E., Shelton, J., Switchenko, J.M., Ross, J.L., McSwain, L.F., Huse, J.T., Westermark, B., Nelander, S., Forsberg-Nilsson, K., Uhrbom, L., Maturi, N.P., Cimino, P.J., Holland, E.C., Kettenmann, H., Brennan, C.W., Brat, D.J. and Hambardzumyan, D.
OncoImmunology 8
(11): e1655360.
22 August 2019
Localization-associated immune phenotypes of clonally expanded tumor-infiltrating T cells and distribution of their target antigens in rectal cancer.
Penter, L., Dietze, K., Ritter, J., Lammoglia Cobo, M.F., Garmshausen, J., Aigner, F., Bullinger, L., Hackstein, H., Wienzek-Lischka, S., Blankenstein, T., Hummel, M., Dornmair, K. and Hansmann, L.
OncoImmunology 8
(6): e1586409.
24 March 2019
2017
Labeling of cell therapies: How can we get it right?
Waiczies, S., Niendorf, T. and Lombardi, G.
OncoImmunology 6
(10): e1345403.
20 July 2017
The splenic marginal zone shapes the phenotype of leukemia B cells and facilitates their niche-specific retention and survival.
Stache, V., Verlaat, L., Gätjen, M., Heinig, K., Westermann, J., Rehm, A. and Höpken, U.E.
OncoImmunology 6
(6): e1323155.
6 June 2017
2016
Transgenic antigen-specific, HLA-A*02:01-allo-restricted cytotoxic T cells recognize tumor-associated target antigen STEAP1 with high specificity.
Schirmer, D., Grünewald, T.G.P., Klar, R., Schmidt, O., Wohlleber, D., Rubio, R.A., Uckert, W., Thiel, U., Bohne, F., Busch, D.H., Krackhardt, A.M., Burdach, S. and Richter, G.H.S.
OncoImmunology 5
(6): e1175795.
25 April 2016
Targeting B-cell neoplasia with T-cell receptors recognizing a CD20-derived peptide on patient-specific HLA.
Mensali, N., Ying, F., Sheng, V.O.Y., Yang, W., Walseng, E., Kumari, S., Fallang, L.E., Kolstad, A., Uckert, W., Malmberg, K.J., Waelchli, S. and Olweus, J.
OncoImmunology 5
(5): e1138199.
18 February 2016
2012
HER2/neu DNA vaccination by intradermal gene delivery in a mouse tumor model: gene gun is superior to jet injector in inducing CTL responses and protective immunity.
Nguyen-Hoai, T., Kobelt, D., Hohn, O., Vu, M.D., Schlag, P.M., Doerken, B., Norley, S., Lipp, M., Walther, W., Pezzutto, A. and Westermann, J.
OncoImmunology 1
(9): 1537-1545.
1 December 2012
This list was generated on Thu Nov 7 12:25:59 2024 UTC.